AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) and Astellas Pharma Inc. Announce Submission of New Drug Application for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC). Tivozanib is designed to target the vascular endothelial growth factor (VEGF) pathway, a clinically validated target in RCC and other solid tumors.